Position
Fidelity in Regeneron Pharmaceuticals, Inc.
Back to the book · All holders of REGN
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$124M$772.64 → $623.54
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 2.32M | $1.79B | — | — | — | 0.1% |
| Q1 2026 | 1.52M | $1.17B | $772.64 | $1.17M | −$618.6M | 0.1% |
| Q2 2026 | 832K | $518.8M | $623.54 | −$124M | −$530.2M | 0.0% |